Shares of Boston Scientific Corp. (NYSE:BSX) traded at unusually high volumes for two straight weeks during the recent roller coast on Wall Street, coming in at more than 120 million trades during the week ending July 29 and topping 140 …
The hedge fund now owns almost $300 million in BSX stock, making the medical technology company its largest holding. According to Marketfolly, Greenlight's six largest disclosed long positions are Arkema, Boston Scientific, CIT Group, …
Boston Scientific Corp. (BSX), Monday said it stopped shipment of its top selling implantable cardioverter defibrillators, as it found some of the manufacturing process changes made were not submitted for approval with the US Food and Drug …
Boston Scientific, which expects to complete its acquisition of Guidant shortly, said yesterday that its first-quarter earnings fell 7.3 percent on slower sales of devices used to treat clogged coronary arteries. But the company, a maker …
In another, the malfunction was discovered when the device was being implanted. Shares of Boston Scientific fell 97 cents to $17.29 in midmorning trading on the New York Stock Exchange. The company's shares last traded in that range in …
... Scientific Corp (BSX.N) rose 6.8 percent after the closing bell on Monday after the company reported results. Its shares were trading at $11 after closing on the New York Stock Exchange at $10.30. Our Standards:The Thomson Reuters …
Boston Scientific Corp. shares climbed after it won approval for ... Analysts also noted that revenue from spinal products was below expectations. The stock was off marginally in recent action to $58.22.
J.’s injury,” he wrote. Johnson & Johnson has moved on from the deal. It received a $705 million breakup fee from Boston Scientific. Since 2004, Johnson & Johnson’s stock has soared 83 percent, and the company is now worth $288 billion. …
LOS ANGELES, Oct 29 (Reuters) - Boston Scientific Corp (BSX.N) Chairman and co-founder Peter Nicholas sold $29.2 million of the company’s stock, or more than 4 million shares that were previously pledged to collateralize loans. The …
Jan 29 (Reuters) - Boston Scientific Corp said on Tuesday that it expected to return to top-line growth this year, an outlook that cheered investors, who bid the medical device maker’s shares up as much as 8 percent to a 1 1/2-year …